Information Provided By: 
Fly News Breaks for June 13, 2016
ELGX
Jun 13, 2016 | 07:21 EDT
As previously reported, Canaccord upgraded Endologix to Buy from Hold as they believe the company has robust momentum coming out of the Society for Vascular Surgery conference, where its full NELLIX data was presented. The firm sees upside to estimates as they see top-line growth and expanded gross margins leading to a multiple expansion. Canaccord raised its price target to $15.50 from $11.25 on Endologix shares.
News For ELGX From the Last 2 Days
There are no results for your query ELGX
